Update on Treatment of Moderate to Severe Asthma with Biologics

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities

Activity Description

New treatments for patients with severe asthma are available to decrease asthma exacerbations, hospitalizations, and oral corticosteroid dosing. This continuing education activity will use a patient case to review the Global Initiative for Asthma (GINA) recommendations, describe type 2 inflammation in asthma and discuss currently available add-on type 2 targeted treatments for severe asthma. Pharmacists will have more confidence assessing severe asthma patients and providing counseling at the completion of this program.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:

  • Review the diagnostic and management approach as outlined by the Global Initiative for Asthma (GINA) network.
  • Describe the pathophysiology of type 2 inflammation in severe asthma.
  • Identify eosinophilic and allergic biomarkers.
  • Compare add-on biologic type 2 targeted treatments and discuss counseling and monitoring parameters for each.


Lori A. Wilken, PharmD, BCACP, NCTTP, AE-C
Clinical Pharmacist, Ambulatory Care
Clinical Assistant Professor, Department of Pharmacy Practice
University of Illinois Hospital and Health Sciences System
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Lori Wilken has received honorarium from Postgraduate Health Ed CE and WebMD as a speaker and content expert, and she has received consulting fees from Optum Rx.

CE Accreditation

Release Date: December 11, 2020
Expiration Date: December 11, 2023


This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-509-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


No external support has been received for this activity.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.